[1] |
Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013[J]. JAMA Oncol, 2015, 1(4):505-527.
doi: 10.1001/jamaoncol.2015.0735
pmid: 26181261
|
[2] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA A Cancer J Clin, 2015, 65(2): 87-108.
doi: 10.3322/caac.21262
URL
|
[3] |
Lingen MW, Kalmar JR, Karrison T, et al. Critical evaluation of diagnostic aids for the detection of oral cancer[J]. Oral Oncol, 2008, 44(1): 10-22.
doi: 10.1016/j.oraloncology.2007.06.011
pmid: 17825602
|
[4] |
D'Cruz AK, Vaish R, Kapre N, et al. Elective versus therapeutic neck dissection in node-negative oral cancer[J]. N Engl J Med, 2015, 373(6): 521-529.
doi: 10.1056/NEJMoa1506007
URL
|
[5] |
Yan M, Yang XH, Wang LZ, et al. Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma[J]. Mol Cell Proteom, 2013, 12(11): 3271-3284.
doi: 10.1074/mcp.M112.025460
URL
|
[6] |
Liu K, Song GQ, Zhang XQ, et al. PTK7 is a novel oncogenic target for esophageal squamous cell carcinoma[J]. World J Surg Oncol, 2017, 15(1): 105.
doi: 10.1186/s12957-017-1172-x
pmid: 28545451
|
[7] |
LiKH, Chen CT, Gao RL, et al. Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia[J]. Biomark Res, 2021, 9(1): 17.
doi: 10.1186/s40364-021-00270-3
pmid: 33663588
|
[8] |
Duan F, Tang J, Kong FL, et al. Identification of PTK7 as a promising therapeutic target for thyroid cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(12): 6809-6817.
|
[9] |
Zou RC, Liang Y, Li LL, et al. Bioinformatics analysis identifies protein tyrosine kinase 7 (PTK7) as a potential prognostic and therapeutic biomarker in stages I toⅣ hepatocellular carcinoma[J]. Med Sci Monit, 2019, 25: 8618-8627.
doi: 10.12659/MSM.917142
URL
|
[10] |
Wang HY, Li GM, Yin YX, et al. PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis[J]. Int J Clin Exp Pathol, 2014, 7(11): 7881-7889.
|
[11] |
Damelin M, Bankovich A, Bernstein J, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions[J]. Sci Transl Med, 2017, 9(372): eaag2611.
doi: 10.1126/scitranslmed.aag2611
URL
|
[12] |
Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches:Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)[J]. Int J Oncol, 2017, 51(5): 1357-1369.
doi: 10.3892/ijo.2017.4129
URL
|
[13] |
Yu BB, Wu KL, Wang X, et al. Periostin secreted by cancer-associated fibroblasts promotes cancer stemness in head and neck cancer by activating protein tyrosine kinase 7[J]. Cell Death Dis, 2018, 9(11): 1082.
doi: 10.1038/s41419-018-1116-6
pmid: 30348980
|
[14] |
Bie J, Hu X, Yang M, et al. PTK7 promotes the malignant properties of cancer stem-like cells in esophageal squamous cell lines[J]. Hum Cell, 2020, 33(2): 356-365.
doi: 10.1007/s13577-019-00309-6
pmid: 31894477
|
[15] |
Berger H, Wodarz A, Borchers A. PTK7 faces the Wnt in development and disease[J]. Front Cell Dev Biol, 2017, 5: 31.
doi: 10.3389/fcell.2017.00031
pmid: 28424771
|
[16] |
Chen G, Qi SC, Yang X, et al. Prognostic significance of PTK7 in human malignancies[J]. Histol Histopathol, 2018, 33(4): 379-388.
doi: 10.14670/HH-11-933
pmid: 28924970
|
[17] |
Hayes M, Naito M, Daulat A, et al. PTK7 promotes non-canonical Wnt/PCP-mediated morphogenesis and inhibits Wnt/β-catenin-dependent cell fate decisions during vertebrate development[J]. Development, 2013, 140(8): 1807-1818.
doi: 10.1242/dev.090183
pmid: 23533179
|